Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 2Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 31Gastrointestinal 14Tumor-Agnostic 7Thoracic 6Other solid neoplasm 5Head & Neck 5CNS 4Sarcoma 3Endocrine 3Dermatologic 3Gynecologic 2Breast 2Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Axitinib × Gynecologic × Clear all
NCT03826589 2025-06-11

ALARICE

The University of Hong Kong

Phase NA Completed
23 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05904730 2024-12-30

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Lynkcell Europe

Phase 1 Completed
10 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡